Ruti Aga's Six-Year Ban: The Punishment Is Not for the Steroid, But for the Clinic That Never Existed

On 10 September, when Ruti Aga was provisionally suspended, few would have guessed that date would stay stamped on a career for six years. On Thursday the Athletics Integrity Unit (AIU) issued its statement and the arithmetic sat there in plain sight: two years for the presence violation, four for tampering, six in total. The central question in this case is not the drug. The central question is the piece of paper that came from a clinic that did not exist, from a "doctor" who was a family member with no medical registration, on an "old prescription pad" that the clinic flatly disowned.

This is the first case I have had to write up where an athlete's sentence came not from the substance but from the paperwork around the substance. That is the most important and least audited fact of the whole story.

Aga's name was not made by this case. The 2026 Tokyo Marathon title and three runner-up finishes at World Marathon Majors belong to an athlete who sat in the 2:18 class — immediately below the world's top stratum, but in the Ethiopian stratum that fights constantly for a national-team place. At 32 she was at the far edge of her peak, where there is no room left for improvement, only room for salvage.

In March she won a half marathon in China. The source gives no time and no field depth, so any comment on that performance would be fabrication. The only usable fact is this: there was an in-competition test after that race, and it came back positive for methylprednisolone. "Won" allows one inference only — that this was a World Athletics Label-tier elite field, where testing exists.

A technical correction is necessary here, because reporting keeps repeating an error. Methylprednisolone is being called a "prohibited steroid" and is described as classed performance-enhancing by WADA. That is incomplete and misleading. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid (S1). The distinction is enormous: S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely lawful. This case is not about "steroid use"; it is about route of administration and timing relative to the competition.

The real audit starts here. The knee doesn't read the calendar — it reads load. For years I have watched road-race broadcast footage frame by frame, and one thing repeats in marathon gait: the knee's job is to accumulate rather than to speak. A weekly pile of 180 to 200 kilometres, at altitude, on hard surfaces, plus travel to Asian label races between Majors — that load returns with interest over months. Synovitis is that interest.

Her post-2026 race-selection profile shows a familiar economy: selective Majors, Asian label races in between. Few starts, high appearance fees. For a 2:18–2:20 marathoner it is a rational model — less tissue load, more wallet. But the same model does something else: it creates pressure to hide a chronic knee problem, because appearance fees go to the athlete who looks like she will stand on the start line, whatever state she is actually in.

And an intra-articular or peri-articular methylprednisolone injection in the knee is standard sports-medicine practice for distance runners — the cheapest, most available tool. Out of competition it is lawful. The problem arises in exactly one place: a road race's testing window opens at 23:59 the night before the race. Even an injection given days earlier can be caught. This is not a drug error, it is a window error — and the fix for a window error is paperwork, not forgery.

This is where the case turns. With a genuine medical record, an explanation of route and timing, and possibly a TUE or a no-significant-fault argument, this case could have run under two years, or not at all. What happened instead is a chain of three independent verification failures: the clinic did not exist; the "doctor" had no medical registration; and the clinic repudiated the "old prescription pad" outright. Three separate checkpoints, three hits.

The sanction arithmetic reads that chain. Two years for the presence violation matches the category where intent is not proven. Four years for tampering is the Code's standard penalty. Add them and you get six. That sum tells us the panel rejected the no-significant-fault mitigation. For the panel the substance case was proven, but the paperwork case weighed heavier still. Backdating to 10 September is a procedural benefit, not a discount — provisional suspension time is credited anyway.

Let me state my limits plainly: I have no GPS, no wellness data, no MRI of that knee, and no record of how many months the treatment had been running. What exists is the public record and a pattern — tampering charges recur in East African road-running cases. That does not mean every athlete is a forger; it means the enforcement frontier has shifted from detection to document verification.

And my real complaint is about the structure nobody examines. Had Aga had a credentialed team physician, this case might never have opened. The professional structure of East African road running is not run by federation medical staff but by agents and informal medical networks. An athlete's "medical support" arrives through that network, where there is no TUE culture. The entourage's medical ledger existed — nobody audited it.

An uncomfortable comparison is owed here. A six-year ban for a substance with no proven endurance benefit will be cited both as evidence of AIU rigour and as evidence of uneven enforcement. I agree with neither camp, because both make the same mistake: they file presence and tampering under one heading.

These are two different things. The first is an injury — a knee treated, at the wrong time, by the wrong route. The second is a different category of error — inventing a prescription from a clinic that never existed. Intent is arguable in the first; not in the second. The place where sympathy belongs is the drug, not the paper. And on the record I will be flat: the ban is filed, the prescription is forged, the clinic is non-existent — documented facts, not debating points.

The real oddity is that six years did not arrive because of six years of anything. Without the paperwork, this case probably ends at two, or at zero. She destroyed the one defence that could have worked. That is not carelessness; it is a design failure — the same design failure that reaches for forgery instead of a counter-investigation.

The AIU cases arriving over the next few months will not turn on which substance was found. They will turn on whose documents can be verified. The data never shouts; it whispers the next breakdown. In this case the whisper came from a clinic's address, not from a finish line.

What would change my mind: evidence that Aga held documented treatment and the entourage chose to replace it. Then this becomes the system's failure rather than the athlete's. Until that surfaces, the question stands: how many more knees in that training cluster will need the same old prescription pad?